منابع مشابه
FDA approves new drug to treat dementia.
Actavis and Adamas Pharmaceuticals, Inc., announced that the U.S. Food and Drug Administration has approved the New Drug Application for NamzaricTM for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on memantine hydrochloride and donepezil hydrochloride. Namzaric will be available in two dosage strengths: 28/10 mg (memantine extended release/donepezi...
متن کاملFDA approves new drug to reduce risk of stroke.
Anew drug to reduce the risk of stroke has received approval from the US Food and Drug Administration. The new drug combines aspirin and dipyridamole into one pill to reduce the risk of stroke for patients who have already had transient ischemic attacks or ischemic strokes caused by blood clots in the brain. Approximately 500 000 people in the United States have strokes each year, and 150 000 d...
متن کاملFDA approves new drug for gastrointestinal stromal tumors.
On February 1, the U.S. Food and Drug Administration (FDA) approved GleevecTM (imantinib mesylate, Novartis Pharmaceuticals, Basel, Switzerland) for the treatment of patients with metastatic or unresectable malignant gastrointestinal stromal tumors (GIST). Gleevec was assessed in a single, open-label randomized trial at one center in Finland and three centers in the United States. A total of 14...
متن کاملFDA approves regorafenib (Stivarga) for metastatic colorectal cancer.
“Stivarga is the latest colorectal cancer treatment to demonstrate an ability to extend patients’ lives, and is the second drug approved for patients with colorectal cancer in the past 2 months,” said Richard Pazdur, MD, director of the office of hematology and oncology products in FDA’s Center for Drug Evaluation and Research, in a press release. In August, the FDA approved aflibercept (Zaltra...
متن کاملFDA approves 11C-choline for PET in prostate cancer.
T he U.S. Food and Drug Administration (FDA) announced on September 12 approval of production and use of 11C-choline for PET imaging in recurrent prostate cancer. The Mayo Clinic PET Radiochemistry Facility (Rochester, MN) will be the first approved facility to produce the tracer injection. 11C-choline must be produced in a specialized facility and must be administered to patients shortly after...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pharmacy Today
سال: 2015
ISSN: 1042-0991
DOI: 10.1016/s1042-0991(15)30378-9